Figure 5.

Recombinant pGP3 alleviated psoriasis-like signs in imiquimod (IMQ)-treated mice, based on histology. Mice were treated with imiquimod for 7 days, then skin biopsies were taken on day 8 and stained with hematoxylin-eosin. (A) Mice treated only with imiquimod showed obvious epidermal thickening, hyperkeratosis, parakeratosis, Munro micro-abscesses and inflammation in dermis. (B) Mice treated with imiquimod and topically treated with pGP3 showed thinner epidermis and less hyperkeratosis, parakeratosis, and inflammation. (C) Similar results were observed in mice treated with imiquimod and injected subcutaneously with pGP3. Regardless of mode of administration, CT795 did not affect histopathology induced by imiquimod.